Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum QLT INC T.QLT

"QLT Inc is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians."

TSX:QLT - Post Discussion

QLT INC > Although hires Strategic Options consultant
View:
Post by TheRock07 on Dec 16, 2014 7:35am

Although hires Strategic Options consultant

QLT Inc
Symbol C : QLT
Shares Issued 51,185,922
Close 2014-12-15 C$ 4.06
Recent Sedar Documents

QLT holders re-elect directors at Dec. 15 AGM

2014-12-16 07:19 ET - News Release

Mr. Jason Aryeh reports

QLT ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

On a vote by ballot, the six incumbent directors of QLT Inc. were re-elected at the company's annual general meeting held on Dec. 15, 2014.

Detailed results of the vote for the election of directors are as tabulated.

  Nominee Votes for % Votes withheld % Jason Aryeh 19,863,451 98.74 254,321 1.26 Dr. Geoffrey Cox, PhD 19,986,585 99.35 131,187 0.65 Dr. John Kozarich, PhD 19,993,991 99.38 123,781 0.62 Jeffrey Meckler 19,854,035 98.69 263,737 1.31 Dr. Stephen Sabba, MD 19,998,081 99.41 119,691 0.59 John Thomas 19,864,082 98.74 253,690 1.26 

Shareholders at the meeting also approved the company's amended and restated advance notice policy.

Final voting results on all matters voted on at the meeting will be filed on SEDAR and EDGAR.

Strategic and business review update

The company also announces that, following the termination of the agreement and plan of merger with Auxilium Pharmaceuticals Inc. in October, 2014, the company continues its review of strategic and business options. The company has engaged Greenhill & Co. to act as adviser to the company in connection with developing, and advising the company with respect to, various strategic and business alternatives for the company. Strategic and business alternatives that the company may consider include, but are not limited to, asset divestiture, partnering or other collaboration agreements, merger, reverse merger, reorganization or similar transactions, potential acquisitions, or recapitalizations, in addition to continuing to operate the company in the ordinary course of business and developing its synthetic retinoid program.

We seek Safe Harbor.

© 2014 Canjex Publishing Ltd. All rights reserved.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities